Neowise Bio Completes Series B Financing to Advance TCR-T Therapies for Solid Tumors

Recently, Neowise Biotechnology, Co., Ltd. (hereinafter referred to as "Neowise Biotechnology" or "the Company") has completed its Series B financing. This round of financing was jointly invested by Yuanhe Holdings, Suzhou Angel Mother Fund, and Tonggao Capital.

Neowise Biotechnology, founded in 2020, is an innovative biotechnology company focused on the research and development of TCR-T immunocyte therapeutic drugs for solid tumors, committed to overcoming the core bottleneck currently faced by cell therapies in the field of solid tumors.

TCR-T cell therapy, as an important branch of adoptive cell therapy, has garnered significant global attention in recent years. Compared to traditional chemotherapy or immune checkpoint inhibitors like PD-1, TCR-T can specifically recognize intracellular tumor antigens, demonstrating notable advantages in disease remission rates and survival benefits for advanced solid tumors. However, a key challenge in this field has long been how to efficiently and safely screen for natural high-affinity TCR sequences from a vast pool of T cells that can precisely target tumor neoantigens.

Addressing this industry pain point, Neowise Biotechnology has independently developed the world's leading "high-throughput, high-sensitivity target antigen-natural TCR discovery and validation platform." This platform innovatively integrates bioinformatics prediction with experimental validation, achieving rapid capture and functional confirmation of extremely low-frequency natural TCRs through a closed-loop feedback mechanism between computational and wet-lab experiments. Currently, the company has built the world’s largest experimentally validated database of target antigen-natural TCR pairs, encompassing thousands of high-quality data entries, significantly broadening the pool of eligible patients for TCR-T therapy.

Relying on a powerful technology platform, Neowise Biotechnology has successfully advanced multiple TCR-T candidate drugs into clinical trial stages. In clinical studies targeting various solid tumors, the company’s products have demonstrated encouraging efficacy and good safety. Notably, the TCR sequences screened by its platform exhibit superior performance across multiple dimensions—such as affinity, tumor-killing activity, and off-target risk control—compared to similar products from leading international pharmaceutical companies.

Currently, the global cell therapy is making in-depth breakthroughs from hematological tumors to solid tumors, and TCR-T is considered one of the key paths to conquering solid tumors. Neowise Biotechnology, with its first-mover technological advantages and solid clinical advancement capabilities, has already taken a significant position in this field. The completion of this Series B round of financing marks the capital market's high recognition of the company’s technical barriers, product potential, and team execution.

In order to enable everyone to learn and communicate with each other better, the media platformWeChat Official Account "Cell Gene Therapy" TeamA WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。